Swedish biotech pairing Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Nasdaq Stockholm: SCOL) have concluded a research collaboration, describing its outcome as positive.
This collaboration was aimed at exploring the anti-tumor efficacy of Alligator’s CD40 antibody mitazalimab in chemotherapy-resistant pre-clinical tumor models as an addition to chemotherapy (FOLFIRINOX) combined with Scandion’s SCO-101.
"Opens the door for harvesting the value of this successful study with larger players"The hypothesis that was tested was to see if SCO-101, as compared to saline control, will revert chemotherapy resistance and thereby facilitate a strengthening of the anti-tumor effects of mitazalimab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze